A little reminder for you all of why you bought PAR originally...

A little reminder for you all of why you bought PAR originally (after a tumultuous week). This research company is actually calling Paradigm at $227.9m in its base case and $318.2m in its bull case valuation - equating to $0.76 per share in our base case and A$1.06 vs present shares on issue.

Sorry many of you will of course forward value PAR far higher, but do remember we are in a very different montetary environment to past and a little caveat - the company, PAR, actually paid for this resarch company to put out the note, so your optimism may supersede the expectations of the company even.

When (ahem, sorry IF) PAR signs partnerships this company expects them to be in the form of licensing deals:

"We assume the company opts for the licensing route and takes a 12% royalty on all sales. We assume a total of A$110.7m of milestone payments, with $10.7m upfront upon execution on the deal during the second half of CY24. We assume $20m upon success of the trial, $20m on regulator submission, $30m on regulatory approval in the USA, $5m on regulatory approval in Australia, $10m upon commencement of sales and $5m on the first anniversary of sales."

Personally I am more optimistic on the upfront payments, but the note might give insight to a likely partnership deal, particularly as the company endorsed the research note.

You will probably have to join up to see the full note, in which they are rather emphatic about its prospects in this very comprehensive analysis. Its Pitt St Research:

https://static1.squarespace.com/static/5af533a312b13fb602fe7d7b/t/66d954574e4aca3b04efe08c/1725518942578/Paradigm+Biophamaceuticals+research+initiation+report+06+09+2024.pdf